Advicenne (PA:ALDVI) — Market Cap & Net Worth
Market Cap & Net Worth: Advicenne (ALDVI)
Advicenne (PA:ALDVI) has a market capitalization of $14.73 Million (€12.60 Million) as of September 20, 2026. Listed on the PA stock exchange, this France-based company holds position #26138 globally and #432 in its home market, demonstrating a -1.93% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Advicenne's stock price €0.87 by its total outstanding shares 14551540 (14.55 Million). Also see balance sheet size of Advicenne for a full breakdown of the balance sheet.
Advicenne Market Cap History: 2017 to 2026
Advicenne's market capitalization history from 2017 to 2026. Data shows change from $233.02 Million to $14.73 Million (-26.99% CAGR). Also see cash flow conversion of Advicenne for how efficiently the company converts equity into cash flow.
Advicenne Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Advicenne's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ALDVI stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
6.74x
Advicenne's market cap is 6.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $233.02 Million | $806.30K | -$4.65 Million | 289.00x | N/A |
| 2018 | $158.67 Million | $1.19 Million | -$4.63 Million | 133.34x | N/A |
| 2019 | $147.00 Million | $2.00 Million | -$14.20 Million | 73.53x | N/A |
| 2020 | $167.04 Million | $2.06 Million | -$14.85 Million | 81.01x | N/A |
| 2021 | $159.02 Million | $2.69 Million | -$12.43 Million | 59.14x | N/A |
| 2022 | $76.34 Million | $2.40 Million | -$11.47 Million | 31.85x | N/A |
| 2023 | $45.25 Million | $4.46 Million | -$7.03 Million | 10.15x | N/A |
| 2024 | $33.51 Million | $4.97 Million | -$6.46 Million | 6.74x | N/A |
Competitor Companies of ALDVI by Market Capitalization
Companies near Advicenne in the global market cap rankings as of September 20, 2026. Review Advicenne tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Advicenne by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #189 globally with a market cap of $128.84 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #340 globally with a market cap of $79.38 Billion USD.
- CSL Ltd (AU:CSL): Ranked #459 globally with a market cap of $60.28 Billion USD ( AU$85.19 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #189 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $128.84 Billion | $508.34 |
| #340 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.38 Billion | $784.85 |
| #459 | CSL Ltd | AU:CSL | $60.28 Billion | AU$175.59 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $154.04 |
Advicenne Historical Marketcap From 2017 to 2026
Between 2017 and today, Advicenne's market cap moved from $233.02 Million to $ 14.73 Million, with a yearly change of -26.99%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €14.73 Million | -49.94% |
| 2025 | €29.43 Million | -12.18% |
| 2024 | €33.51 Million | -25.94% |
| 2023 | €45.25 Million | -40.72% |
| 2022 | €76.34 Million | -52.00% |
| 2021 | €159.02 Million | -4.80% |
| 2020 | €167.04 Million | +13.64% |
| 2019 | €147.00 Million | -7.36% |
| 2018 | €158.67 Million | -31.91% |
| 2017 | €233.02 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 20th, 2026 the market cap of Advicenne was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.73 Million USD |
| MoneyControl | $14.73 Million USD |
| MarketWatch | $14.73 Million USD |
| marketcap.company | $14.73 Million USD |
| Reuters | $14.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more